Founded in 2014, Kiyun Wellcome is a startup that specializes in the storage, interpretation and application of human genome-wide data. The company specializes in personal genome-wide data analysis and interpretation. Its self-developed Genome Analysis and Interpretation in Cloud GAIC can analyze and interpret human genome data at a faster rate and at a lower cost. It has obtained the qualifications of Zhongguancun High-tech Enterprise and National High-tech Enterprise, and has successfully participated in the national “ precise medical †project.
Established: Take the whole direction of genome-wide data
Prior to founding Kevin Wellcome, Hao Xiangwen had worked in two of the world's most famous genetic companies, Huada Gene and Illumina. In 2003, Hao Xiangwen, who just graduated, entered the work of Huada Gene. Hao Xiangwen recalled: "In the student era, I was very concerned about Huada's genes. I feel very lucky to have a lot of benefits when I enter China University." He told reporters that in the years of Huada, not only did he have a deeper understanding of genetic technology, but also I have met many like-minded friends.
In 2014, Hao Xiangwen gave birth to the idea of ​​starting a business because he was always at the forefront of the genetic industry, coupled with his own interests. The work experience of Huada and Illumina has given him a deep understanding of the industry. He knows very well that genetic technology has developed to the present stage and is already a highly standardized technology. Genetic technology itself is difficult to differentiate, and advances in sequencing technology and cost reductions are bound to increase the difficulty of data processing. So he proposed: take the whole direction of genome-wide data.
Hao Xiangwen told reporters: "I am a student of technology, but I don't have experience in big data processing, so I hope to find a partner." At Illumina, Hao Xiangwen met his current partner, the Beijing Institute of Life Sciences, Chinese Academy of Sciences. Wu Jinyu. Before the partnership, Wu Jinyu has been doing research on autism, investing a lot of energy and resources in the genome-wide data. The two hit it off, and Jiyun Wellcome was established.
Hundred People Genome Project, Verifying the Validity of Gene Sequencing Data
At the beginning of its establishment, Jiyun Wellcome launched the “Hundred People Genome Projectâ€. The program was completed in June last year and is divided into three parts: genome-wide testing, routine physical examination, and wearables to verify the combination of genetic sequencing data with physical and wearable data. Hao Xiangwen revealed to the reporter: "The analysis and interpretation of the test data, although the technology has been achieved, but to practical application, it needs to be verified first."
This event enabled more people to understand Jiyun Wellcome. During this period, Jiyun Wellcome gradually completed the completion of the basic technology.
The company completed the Angel Wheel financing in May 2015. When talking about the financing process, Hao Xiangwen felt very coincidental. At that time, the Internet was rapidly emerging. Hao Xiangwen hopes to find investors with an Internet background to understand the thinking and operation mode of the Internet.
After the first investor Zheng Jie introduced the investor Wang Gang. Coincidentally, Wang Gang himself hopes to invest in cutting-edge technology companies like genetic technology. After the meeting, the two chatted very speculatively and the financing process was relatively smooth. After that, Hao Xiangwen also participated in the "Winners League" initiated by Wang Gang. Through exchanges, he deepened his understanding of the Internet. "The foundation of Kiyun Wellcome is a cross-border thing, and it needs more communication collisions with the Internet industry." Hao Xiangwen said.
Clarithromycin Tablets,Clarithromycin Tablet,Anti-Infective Drug,Macrolide Antibiotics Drug
SHANDONG XINHUA PHARMACEUTICAL Co., Ltd. , https://www.sdxinhuapharm.com